JNC Showcased Chromatography Products for Viral Vectors
The company presented research-stage media designed to purify large biological particles more efficiently.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe new pharmaceutical manufacturing technologies will lead to better health outcomes?
JNC showcased its Cellufine chromatography portfolio and new MLP platform at BioProcess International 2026. The company presented research-stage performance data for its DexQ and DexS products, which aim to improve purification for viral vectors.
Why it matters
As biopharmaceutical manufacturers grapple with the growing physical size of therapeutic biological molecules, existing purification columns often struggle to capture large targets. JNC is positioning its large-pore media to address these scaling challenges in viral vector production.
The MLP platform uses a large-pore bead architecture designed to improve access to target molecules. During influenza testing, the Cellufine MLP DexS ligand concentrated inactivated virus 13-fold while reducing protein impurities by 90.3%.
The players
JNC
A chemical and materials company that develops specialized chromatography media and filtration products for the biopharmaceutical industry.
The details
The technology centers on a large-pore bead structure that facilitates the flow and capture of bulky biological particles. Cellufine MLP DexS utilizes dextran sulfate—a complex sugar molecule used as a binding agent—to selectively capture target particles while filtering out proteins. Researchers also demonstrated that Cellufine MLP DexQ can distinguish between full and empty adeno-associated virus particles, a persistent challenge in gene therapy manufacturing.
Timeline
JNC showcased the Cellufine portfolio during the BioProcess International 2026 conference in September 2026.
The Tech Race
The pursuit of efficient viral vector purification is a primary race in the biopharmaceutical sector, where production costs are heavily influenced by yield and purity. JNC is competing to expand its conventional column chromatography presence into the niche of large-particle separation.
These purification media are currently in the research and development phase and are not yet available for commercial manufacturing workflows. Biopharmaceutical engineers should monitor JNC for future performance benchmarks and product availability timelines.
The takeaway
The effectiveness of these chromatography products hinges on their ability to handle larger viral particles than traditional bead architectures allow. Watch for future peer-reviewed studies that validate these purification rates at a pilot-plant scale.
Further reading
Learn more about the latest innovations in production technology at Biotech.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Do you believe new pharmaceutical manufacturing technologies will lead to better health outcomes?
